(Q35199419)

7 August 2017

0 references

1 reference

title

Colony stimulating factors for chemotherapy induced febrile neutropenia (English)

1 reference

chemotherapy-induced febrile neutropenia

7 August 2017

main subject

0 references

1 reference

O A C Clark

1

1 reference

7 August 2017

G Lyman

2

1 reference

7 August 2017

A A Castro

3

1 reference

7 August 2017

L G O Clark

4

1 reference

7 August 2017

B Djulbegovic

5

1 reference

7 August 2017

publication date

1 January 2003

1 reference

Cochrane Database of Systematic Reviews

7 August 2017

published in

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

CD003039

1 reference

Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Effect of recombinant human granulocyte colony stimulating factor (lenograstim) on chemotherapy induced neutropenia in patients with urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind contro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Granulocyte-Colony Stimulating Factor (G-CSF) Administration for Chemotherapy-Induced Neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Infectious complications of febrile leukopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Use of re-randomized data in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Using numerical results from systematic reviews in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Fever in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Colony stimulating factors in patients with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Effectiveness of home care programmes for patients with incurable cancer on their quality of life and time spent in hospital: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Systematic Reviews in Health Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced granulocytopenia in patients with malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

1997 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

Statistical considerations in clinical trials testing empiric antibiotic regimens in patients with febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003039

10.1002/14651858.CD003039

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference